Covaxin
After Pfizer and Serum Institute, Bharat Biotech seeks DCGI approval for emergency use of Covaxin
New Delhi/IBNS: After Pfizer and Serum Institute, Hyderabad-based pharmaceutical company Bharat Biotech has sought approval from the Drug Controller General of India (DCGI) for the emergency use authorisation (EUA) of its Covid-19 vaccine-Covaxin, media reports said.
Bharat Biotech International Limited (BBIL) has developed Covaxin indigenously in partnership with the Indian Council of Medical Research (ICMR).
This is the third request received by the DCGI in the last two days.
Bharat Biotech's vaccine candidate-Covaxin had received the nod of the DCGI on Jun 30 last.
On Dec 4, Prime Minister Narendra Modi at an all-party meeting had stated that a Covid-19 vaccine may be ready in a few weeks.
Earlier, the Serum Institute of India (SII) has applied for an emergency approval from the Indian government of its vaccine against Covid-19, named Covishield.
SII CEO and owner Adar Poonawalla tweeted on Monday: "As promised, before the end of 2020, Serum Institute of India has applied for emergency use authorisation for the first made-in-India vaccine, COVISHIELD. This will save countless lives, and I thank the Government of India and Sri Narendra Modi ji for their invaluable support."
Health workers and elderly people suffering from the deadly disease will be the first set of people to be vaccinated, the PM had said.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
